Vetdrugs 2.0Pantoprazole is a proton-pump inhibitor used for suppression of gastric acid secretion. Its veterinary role includes acid-related upper gastrointestinal disease, especially when an intravenous formulation is useful. Delayed-release oral preparations provide another delivery option. Clinical applications focus on reducing acid exposure at injured gastric, duodenal or esophageal mucosa.
Group
Proton-pump inhibitor
Mechanism of Action
Pantoprazole is activated in the acidic secretory canaliculi of gastric parietal cells. The active compound forms covalent bonds with the hydrogen–potassium ATPase, inhibiting the final step of gastric acid secretion. Suppression of both basal and stimulated acid output raises gastric pH, reducing acid-mediated tissue injury and supporting healing of responsive upper gastrointestinal lesions.
Dose Rates
Dogs
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Ulceration or reflux | 0.5–0.6 mg/kg | PO | Every 12 h | Published regimens allow escalation up to 1 mg/kg; use the separate higher-dose record rather than assuming every case requires the maximum. |
| Higher-dose acid suppression | 1 mg/kg | PO | Every 12 h | For selected refractory or hypersecretory cases. |
| Parenteral acid suppression | 1 mg/kg | IV | Administer over 2 minutes using a verified 4 mg/mL stock, or over 15 minutes after compatible dilution. A repeat interval must be prescribed separately. | |
| Continuous IV acid suppression | Reference only | IV | A described 0.5–1 mg/kg IV amount has inconsistent administration-duration wording (24 hours versus 2 or 15 minutes). A continuous protocol requires clarification of daily total and delivery duration before use. | |
| Intermittent parenteral acid suppression | 0.5–1 mg/kg | IV | Every 24 h | Infuse over 15 minutes. Distinct from the ambiguously described 24-hour infusion. |
| Stress-related mucosal disease | 0.7–1 mg/kg | IV | Every 24 h | Administer the injectable formulation IV; do not use IM or SC. |
Cats
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Ulceration or reflux | 0.5–0.6 mg/kg | PO | Every 12 h | Published regimens allow escalation up to 1 mg/kg; use the separate higher-dose record rather than assuming every case requires the maximum. |
| Higher-dose acid suppression | 1 mg/kg | PO | Every 12 h | For selected refractory or hypersecretory cases. |
| Parenteral acid suppression | 1 mg/kg | IV | Administer over 2 minutes using a verified 4 mg/mL stock, or over 15 minutes after compatible dilution. A repeat interval must be prescribed separately. | |
| Continuous IV acid suppression | Reference only | IV | A described 0.5–1 mg/kg IV amount has inconsistent administration-duration wording (24 hours versus 2 or 15 minutes). A continuous protocol requires clarification of daily total and delivery duration before use. | |
| Intermittent parenteral acid suppression | 0.5–1 mg/kg | IV | Every 24 h | Infuse over 15 minutes. Distinct from the ambiguously described 24-hour infusion. |
Horses
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Neonatal foal gastric acid suppression | 1.5 mg/kg | IV | Every 24 h | Experimental PK/PD course in normal neonatal foals; efficacy in critically ill foals was not established. Not an adult-horse dose. |
Indications
- Treatment of selected gastroduodenal ulceration or acid-related erosive disease in dogs, cats, foals or other supported veterinary patients.
- Acid suppression in selected reflux esophagitis.
- Management of selected gastric hypersecretory states, including gastrinoma-associated disease.
- Prevention of acid-related mucosal injury in selected patients with a defined high-risk disorder.
Contraindications
- Benzimidazole hypersensitivity
Interactions
- May reduce absorption of medicines requiring an acidic gastric environment, including some azole antifungals and iron salts.
- Do not admix IV solution with other drugs.
- Sucralfate may reduce oral bioavailability.
- Warfarin anticoagulant effect may increase; monitor if used together.
Adverse effects
- Gastrointestinal disturbance
- Potential complications of prolonged acid suppression
Toxicity
Significant overdose requires supportive assessment; prolonged unnecessary use should be avoided.
Preparations
| Preparation | Form | Strength | Route |
|---|---|---|---|
| Pantoprazole delayed-release tablets 20 mg Do not crush or chew; a fractional mathematical tablet equivalent does not preserve delayed-release delivery. Whole tablets only. | Tablet | 20 mg / tablet | PO |
| Pantoprazole delayed-release tablets 40 mg Do not crush or chew; a fractional mathematical tablet equivalent does not preserve delayed-release delivery. Whole tablets only. | Tablet | 40 mg / tablet | PO |
| Pansec enteric-coated tablets 40 mg Pantoprazole equivalent supplied as sodium sesquihydrate. Swallow intact; do not crush or chew. Whole tablets only. | Tablet | 40 mg / tablet | PO |
| Pantoprazole IV vial 40 mg Use exact product instructions. Published formulation information describes 10 mL saline reconstitution giving 4 mg/mL; do not calculate an assumed final diluted volume. | Injection | 40 mg / vial | IV |
Monitoring and Administration
For delayed-release tablets, do not crush or chew. Administration before feeding may improve effect.
For a compatible 40 mg IV vial, a verified 4 mg/mL stock is obtained with the specified 10 mL saline reconstitution. A further 100 mL addition gives about 110 mL total and 0.364 mg/mL, not exactly 0.4 mg/mL. Use an explicitly prescribed final volume for the intended concentration.
Continuous infusion and short IV administration are distinct protocols. Use an explicitly specified duration, final concentration and product-specific validated stability.
Monitor vomiting, diarrhea and evidence of GI bleeding; follow CBC/hematocrit when hemorrhage is suspected.
For oral suspension, use a pharmacy-validated formulation with specified tablet strength, final volume and beyond-use period; do not improvise from an incomplete compounding recipe.
Injectable pantoprazole is IV only. Give the 4 mg/mL stock over no less than 2 minutes and stop for particulate formation or discoloration. Do not admix with midazolam; zinc-containing solutions may be incompatible.
A separate manufacturer-derived description used 2 hours at room temperature for the 10 mL reconstituted stock and 22 hours after further infusion dilution; longer periods reported elsewhere cannot be transferred between formulations.
Delayed-release tablets must remain whole: no splitting, crushing or chewing.